source
- Versa Vascular appoints former Medtronic heart franchise leader Bill Shields as CEOBill Shields, who spent 15 years leading Medtronic’s structural heart franchise, is leaving the medtech giant to become chief executive of Versa Vascular, a startup developing tricuspid valve repai…
- Zealand Pharma sells its rights to Takeda's rusfertide for $100 million ahead of FDA decisionZealand Pharma has agreed to sell its economic interest in rusfertide, a peptide drug being developed by Takeda and Protagonist Therapeutics, for $100 million. The transaction comes as the FDA rev…